We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

173 hedge funds and large institutions have $783M invested in Nurix Therapeutics in 2025 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 49 increasing their positions, 60 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

981% more call options, than puts

Call options by funds: $1.12M | Put options by funds: $104K

42% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 24

6% more funds holding

Funds holding: 163 → 173 (+10)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4.96% less ownership

Funds ownership: 115.85% → 110.89% (-5%)

18% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 60

22% less capital invested

Capital invested by funds: $1.01B → $783M (-$223M)

Holders
173
Holders Change
+10
Holders Change %
+6.13%
% of All Funds
2.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
34
Increased
49
Reduced
60
Closed
24
Calls
$1.12M
Puts
$104K
Net Calls
+$1.02M
Net Calls Change
-$528K

Top Buyers

1
VPC
Vestal Point Capital
New York
+$15.3M
2
Deutsche Bank
Deutsche Bank
Germany
+$11.1M
3
KCM
Kynam Capital Management
New Jersey
+$10.3M
4
Millennium Management
Millennium Management
New York
+$6.19M
5
AG
Algert Global
California
+$4.67M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$20.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$16.1M
3
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$13.3M
4
UBS Group
UBS Group
Switzerland
-$12.7M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$12.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Qube Research & Technologies (QRT)
26
Qube Research & Technologies (QRT)
United Kingdom
$6.62M +$3.74M +359,793 +101%
Northern Trust
27
Northern Trust
Illinois
$6.28M +$275K +26,476 +4%
Goldman Sachs
28
Goldman Sachs
New York
$5.75M +$392K +37,780 +6%
Citadel Advisors
29
Citadel Advisors
Florida
$5.22M -$10.6M -1,023,730 -64%
AG
30
Algert Global
California
$5.21M +$4.67M +449,338 +392%
Handelsbanken Fonder
31
Handelsbanken Fonder
Sweden
$4.8M +$2.49M +240,000 +86%
Bank of America
32
Bank of America
North Carolina
$4.44M +$1.6M +153,843 +47%
PSC
33
Patient Square Capital
California
$4.04M +$259K +24,941 +6%
Dimensional Fund Advisors
34
Dimensional Fund Advisors
Texas
$3.98M +$40.4K +3,891 +0.9%
UBS Group
35
UBS Group
Switzerland
$3.35M -$12.7M -1,226,494 -77%
IHAM
36
Integral Health Asset Management
New York
$3.23M +$415K +40,000 +13%
RPAM
37
Rhenman & Partners Asset Management
Sweden
$3.21M +$1.69M +162,500 +88%
CSS
38
Cubist Systematic Strategies
Connecticut
$3.03M +$3.41M +327,952 New
ACH
39
ArrowMark Colorado Holdings
Colorado
$2.91M – – –
WA
40
Wasatch Advisors
Utah
$2.9M -$1.8M -173,047 -36%
Bessemer Group
41
Bessemer Group
New Jersey
$2.83M – – –
CS
42
Candriam SCA
Luxembourg
$2.42M – – –
Jane Street
43
Jane Street
New York
$2.39M +$2.69M +258,651 New
Wellington Management Group
44
Wellington Management Group
Massachusetts
$2.36M -$12.6M -1,209,263 -83%
Marshall Wace
45
Marshall Wace
United Kingdom
$2.28M +$2.56M +246,788 New
KCM
46
Kennedy Capital Management
Missouri
$2.28M -$115K -11,073 -4%
Barclays
47
Barclays
United Kingdom
$2.26M -$102K -9,775 -4%
Ensign Peak Advisors
48
Ensign Peak Advisors
Utah
$2.13M – – –
Bank of New York Mellon
49
Bank of New York Mellon
New York
$2.11M +$48.1K +4,633 +2%
WFA
50
WestHill Financial Advisors
California
$2.11M – – –
1
2
3 4 5

NRIX Hedge Fund Activity: Q3 2025 in Review

173 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2025, worth a combined $783M — down 22% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new NRIX positions and 24 closed out — a net gain of 10 holders — while 49 added to existing stakes and 60 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $15.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $20.1M.

  • 173 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2025, up from 163 in Q2 2025.
  • Funds reported $783M of Nurix Therapeutics stock for Q3 2025, down 22% quarter-over-quarter.
  • 34 funds opened new Nurix Therapeutics positions in Q3 2025 and 24 closed out, a net change of +10 holders.
  • The largest Nurix Therapeutics buyer in Q3 2025 was Vestal Point Capital, an estimated $15.3M added.
  • The largest Nurix Therapeutics seller in Q3 2025 was T. Rowe Price Associates, an estimated $20.1M sold.

Based on aggregated 13F filings for Q3 2025.